GWP.L Regulatory News (GWP)

GW Pharmaceuticals PLC

Total Voting Rights - Voting Rights and Capital

London, UK, 9 May 2013: GW Pharmaceuticals (NASDAQ:GWPH, AIM: GWP, "GW" or the "Company") a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, in conformity with 5.6.1 of the Disclosure and Transparency Rules, today notifies the market of the following: 

The Company's issued share capital consists of 175,370,354 Ordinary Shares of 0.1p each with voting rights.

The Company does not hold any shares in Treasury.

The above figure of 175,370,354 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company under the FSA's Disclosure and Transparency Rules.

About GW Pharmaceuticals plc

Founded in 1998, GW is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. GW commercialized the world's first plant-derived cannabinoid prescription drug, Sativex®, which is approved for the treatment of spasticity due to multiple sclerosis in 21 countries. Sativex is also in Phase 3 clinical development as a potential treatment of pain in people with advanced cancer. This Phase 3 program is intended to support the submission of a New Drug Application for Sativex® in cancer pain with the U.S. Food and Drug Administration and in other markets around the world. GW has established a world leading position in the development of plant-derived cannabinoid therapeutics and has a deep pipeline of additional cannabinoid product candidates, including two distinct compounds, GWP42004 and GWP42003, in Phase 2 clinical development for Type 2 diabetes and ulcerative colitis, respectively, and at least two additional programs expected to enter Phase 1 and Phase 2 clinical trials in the next 12 months. For further information, please visit www.gwpharm.com.

Enquiries:

GW Pharmaceuticalsplc

Tel: +44 (0)1980 557 000

Peel Hunt LLP(Nominated Adviser)

Tel: +44 (0)207 418 8900

James Steel/Vijay Barathan